Can Viagra help revive this biotech company?

Drawing on more than $100 million to push its marquee drug into human clinical trials, Cleave Biosciences Inc. promised to open a new front in the war on cancer. Instead, following a clinical trial failure, Cleave’s CEO and all but a caretaker crew have departed, leaving the Burlingame company with two experimental drugs and little more than hope for a revival or a fire sale. Cleave’s story is common in biotech, where nearly nine of 10 drugs that ente r human testing fail to make it to market.…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news